DRI Healthcare Trust (DHT-UN) Corporate presentation summary

Business overview and strategy

• Specializes in pharmaceutical royalty monetization, providing capital to advance innovation in the life sciences sector.

• Holds a diversified portfolio of royalty interests in drugs addressing significant unmet needs, marketed by leading biotech and pharma companies.

• Sourcing spans the entire drug development value chain, including inventors, academic institutions, drug developers, and marketers.

• Employs a proprietary database tracking royalties on over 2,500 drugs and leverages deep industry relationships for proactive deal sourcing.

• Rigorous due diligence process includes commercial, scientific, IP, regulatory, and legal assessments.

Portfolio and financial performance

• Portfolio consists of 28 royalty streams on 22 products, with no single product exceeding 25% of net book value.

• Therapeutic area allocation includes oncology (23%), ophthalmology (33%), immunology (17%), and hematology (16%).

• For the twelve months ended June 30, 2026: $209M total income, $178M adjusted EBITDA, and 90% adjusted EBITDA margin.

• Q2 2026 financials: $46.5M total cash receipts (up 16% YoY), $50.1M total income (up 13% YoY), $42.6M adjusted EBITDA (up 40% YoY), and $0.56 adjusted cash earnings per unit.

• Strong cash generation supports portfolio growth and unitholder distributions.

Key transactions and growth drivers

• Completed 16 royalty transactions since IPO, deploying over $1.25B, with significant deals in assets like Lumvoa, Ekterly, Casgevy, Omidria, Orserdu, Vonjo, and Tzield.

• Notable transactions include Lumvoa ($55M upfront + $75M milestone), Ekterly ($100M upfront + $5M PIPE), Casgevy ($57M upfront), and Omidria ($115M upfront + up to $27.5M milestones).

• Growth opportunities from existing assets include additional indications and ongoing clinical trials for key products.

• Pipeline of over $3B in potential opportunities under active evaluation as of June 30, 2026.